Researchers from Pfizer, BioNTech and the Galveston-based University of Texas Medical Branch analyzed blood samples of 15 patients who had received the vaccine to see how well it fought against a coronavirus designed to have the same mutations found in B.1.351. They found a 66 percent decrease in neutralization capabilities when compared to earlier versions of the novel coronavirus.
The research team said it’s still unclear what this finding may mean for the vaccine’s efficacy in humans, as further research needs to be conducted.
AstraZeneca, Johnson & Johnson and Novavax have also recently released preliminary clinical data showing their COVID-19 vaccines are not as effective at preventing symptomatic COVID-19 cases caused by B.1.351.
More articles on pharmacy:
US boosts states’ weekly vaccine allotment to 13.5M doses
Half of patients got prescriptions through mail order in 2020, survey says
Two-thirds of pharmacists have taken on new job responsibilities since COVID-19, survey finds
but said it’s still unclear what this finding may mean for the vaccine’s efficacy in people.
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
